Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

Overview

Integrity signals

Registry

Crossref · 10.1016/s0959-8049(20)31076-5

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Still being checked.

Cited by

See all 150

Metadata

Authors
Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., Pacheco, J. M., Leal, T. A., Velastegui, K., Cornelius, C., Olson, P., Christensen, J. G., Kheoh, T., Chao, R. C., & Ou, S. H. I.
Affiliations
  • Henry Ford Hospital (US)
  • Virginia Cancer Specialists (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • South Texas Accelerated Research Therapeutics (US)
  • NYU Langone Health (US)
  • Sarah Cannon (US)
  • Massachusetts General Hospital (US)
  • University of California San Diego (US)
  • University of Colorado Cancer Center (US)
  • University of Wisconsin–Madison (US)
  • Mirati Therapeutics (United States) (US)
  • University of California, Irvine (US)
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2020-10
Volume
138
Pages
S1-S2
ISSN
0959-8049 (ISSN-L)
OpenAlex
W3097627562
Cited by
140
References
0
Citations by year
2026: 5 · 2025: 9 · 2024: 11 · 2023: 16 · 2022: 39 · 2021: 59 · 2020: 1
FWCI
16.21
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
European Journal of Cancer (publishedVersion)
Funders
  • AstraZeneca
  • Daiichi Sankyo Company
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
adagrasib, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, lung adenocarcinoma, drug safety, anticancer activity, covalent inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation. https://app.cochat.ai/papers/10.1016/s0959-8049(20)31076-5
The paper
Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., Pacheco, J. M., Leal, T. A., Velastegui, K., Cornelius, C., Olson, P., Christensen, J. G., Kheoh, T., Chao, R. C., & Ou, S. H. I. (2020). KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(20)31076-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.